1. TF is newly diagnosed with stage IIIB non-small cell lung cancer (NSCLC). Molecular testing was conducted, and TF is negative for sensitizing mutations. Programmed death-ligand 1 (PD-L1) testing is currently pending. TF can perform most daily activities but needs assistance for some tasks. Eastern Cooperative Oncology Group Performance Status (ECOG PS) is estimated to be 1. Following tumor board, the team decides that TF has an inoperable tumor. Which of the following treatment schema is the most appropriate regimen for TF?

2. LP is newly diagnosed with stage II NSCLC. Molecular testing was conducted, and LP is negative for sensitizing mutations. She is PD-L1 positive, >50%. She walks daily and performs all her daily activities. Following tumor board review, the team decides to treat her with a neoadjuvant approach. Which of the following is the most appropriate regimen for her?

3. RP is a 65-year-old man on treatment with durvalumab every 2 weeks for his diagnosis of stage IIIB NSCLC that was determined to be inoperable. He is experiencing grade III pneumonitis. What treatment would you consider recommending?

4. KO is a 54-year-old man being considered for treatment with adjuvant pembrolizumab for his diagnosis of stage II NSCLC. His current medication list consists of atorvastatin 20 mg daily, prednisone 5 mg daily for rheumatoid arthritis, omeprazole 20 mg daily, and aspirin 81 mg daily. Based on his medication list, which drug would you advise to be held prior to starting treatment with an ICI?

« Return to Activity